BioNexus Gene Lab (BGLC) Return on Sales (2018 - 2026)

BioNexus Gene Lab (BGLC) has 9 years of Return on Sales data on file, last reported at 0.24% in Q1 2026.

• For the quarter ending Q1 2026, Return on Sales fell 24.0% year-over-year to 0.24%; the trailing twelve-month figure through Mar 2026 stood at 0.01% (changed 0.0% YoY), and the FY2025 full-year result was 0.0%, changed 0.0% from the prior year.
• Return on Sales declined to 0.24% in Q1 2026, from 0.02% in the prior quarter.
• In the past five years, Return on Sales ranged from a high of 0.0% in Q4 2023 to a low of 0.24% in Q1 2026.
• A 5-year average of 0.02% and a median of 0.0% in 2023 frame the typical range for Return on Sales.
• Across the five-year window, Return on Sales grew 1 bps in 2024 and dropped 24 bps in 2026, its largest moves.
• Tracing BGLC's Return on Sales over 5 years: stood at 0.0% in 2022, then soared by 567 bps to 0.0% in 2023, then tumbled by 184 bps to 0.0% in 2024, then plunged by 1543 bps to 0.02% in 2025, then slumped by 1011 bps to 0.24% in 2026.
• Business Quant data shows BGLC's Return on Sales at 0.24% in Q1 2026, 0.02% in Q4 2025, and 0.0% in Q3 2025.